Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma
Yidan Zhang(Hebei Medical University), Bang H. Hoang(Albert Einstein College of Medicine), Kenji Satô(Albert Einstein College of Medicine), Nikolas Zaphiros(Albert Einstein College of Medicine), Jinghang Zhang(Albert Einstein College of Medicine), Richard Görlick(The University of Texas MD Anderson Cancer Center), Xiaolin Zi(University of California, Irvine), Jonathan Gill(Albert Einstein College of Medicine), Michael Roth(The University of Texas MD Anderson Cancer Center), Deyou Zheng(Merck & Co., Inc., Rahway, NJ, USA (United States)), David S. Geller(Albert Einstein College of Medicine), Yoav S. Zvi(Albert Einstein College of Medicine), Sajida Piperdi(Albert Einstein College of Medicine), Jichuan Wang(Albert Einstein College of Medicine), Rui Yang(Gansu Agricultural University), B Batko(Albert Einstein College of Medicine), Yang Liu(Albert Einstein College of Medicine), Wendong Zhang(North University of China), Tingting Ren(Peking University), Edmond F. O’Donnell(Oregon State University), Xiuquan Du(Albert Einstein College of Medicine), Pratistha Koirala(Fox Chase Cancer Center)
Cited by 98
Related Papers
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance
|Clinical Cancer Research|2021|420
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419